← All trials
NCT03018535
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2012
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of BresciaLead sponsor
- University of BresciaReponsible party - principal investigator
- University of VeronaCollaborator
- University of BariCollaborator
- Azienda Ospedaliera BrotzuCollaborator
- University of MessinaCollaborator
- University of MilanCollaborator
- University of BolognaCollaborator
- University of Modena and Reggio EmiliaCollaborator
- University of PisaCollaborator
- Azienda Ospedaliera Universitaria PoliclinicoCollaborator
- University of BernCollaborator
- University of AlbertaCollaborator
- University of GenoaCollaborator
- D'Annunzio University of Chieti–PescaraCollaborator
- Azienda Sanitaria Locale Roma ECollaborator
- University of PaviaCollaborator
- Humanitas UniversityCollaborator
- University of BresciaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.